These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 26056742)

  • 1. New approaches to HIV vaccine development.
    Haynes BF
    Curr Opin Immunol; 2015 Aug; 35():39-47. PubMed ID: 26056742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
    Subbaraman H; Schanz M; Trkola A
    Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.
    Burton DR; Hangartner L
    Annu Rev Immunol; 2016 May; 34():635-59. PubMed ID: 27168247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention.
    Stephenson KE; Wagh K; Korber B; Barouch DH
    Annu Rev Immunol; 2020 Apr; 38():673-703. PubMed ID: 32340576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
    Sadanand S; Suscovich TJ; Alter G
    Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions.
    Rubens M; Ramamoorthy V; Saxena A; Shehadeh N; Appunni S
    J Immunol Res; 2015; 2015():560347. PubMed ID: 26579546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers.
    Landais E; Moore PL
    Retrovirology; 2018 Sep; 15(1):61. PubMed ID: 30185183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlates of broadly neutralizing antibody development.
    Abela IA; Kadelka C; Trkola A
    Curr Opin HIV AIDS; 2019 Jul; 14(4):279-285. PubMed ID: 31107283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
    Ahmed Y; Tian M; Gao Y
    AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development.
    Bonsignori M; Liao HX; Gao F; Williams WB; Alam SM; Montefiori DC; Haynes BF
    Immunol Rev; 2017 Jan; 275(1):145-160. PubMed ID: 28133802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.
    Verkoczy L; Alt FW; Tian M
    Immunol Rev; 2017 Jan; 275(1):89-107. PubMed ID: 28133799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host controls of HIV broadly neutralizing antibody development.
    Kelsoe G; Haynes BF
    Immunol Rev; 2017 Jan; 275(1):79-88. PubMed ID: 28133807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in HIV-1 vaccine development.
    Haynes BF; Moody MA; Alam M; Bonsignori M; Verkoczy L; Ferrari G; Gao F; Tomaras GD; Liao HX; Kelsoe G
    J Allergy Clin Immunol; 2014 Jul; 134(1):3-10; quiz 11. PubMed ID: 25117798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broadly Neutralizing Antibody-Guided Carbohydrate-Based HIV Vaccine Design: Challenges and Opportunities.
    Liu CC; Zheng XJ; Ye XS
    ChemMedChem; 2016 Feb; 11(4):357-62. PubMed ID: 26762799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting broadly neutralizing antibody precursors: a naïve approach to vaccine design.
    McGuire AT
    Curr Opin HIV AIDS; 2019 Jul; 14(4):294-301. PubMed ID: 30946041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological mechanisms of inducing HIV immunity in infants.
    Fouda GG; De Paris K; Levy O; Marchant A; Gray G; Permar S; Marovich M; Singh A
    Vaccine; 2020 Jan; 38(3):411-415. PubMed ID: 31761501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
    Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in HIV vaccine development.
    Hsu DC; O'Connell RJ
    Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.